Neuberger Berman Group
TTPH

Neuberger Berman Group’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Neuberger Berman Group’s Portfolio TTPH Stock Details TTPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,123
Closed -$141K – 1782
2017
Q4 		$141K Buy
+1,123
New +$144K ﹤0.01% 1714

Other funds holding TTPH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Neuberger Berman Group's TTPH Position: Q1 2018 in Review

Neuberger Berman Group sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q1 2018, closing a stake of 1,123 shares — an estimated $141K sold.

Neuberger Berman Group first reported a position in TTPH in Q4 2017 and held it in 1 quarter. The position peaked at $141K in Q4 2017. 94 funds tracked by Wall St. Rank hold TTPH as of Q1 2018.

  • Neuberger Berman Group reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
  • Neuberger Berman Group sold 1,123 Tetraphase Pharmaceuticals, Inc. shares in Q1 2018, an estimated $141K.
  • Neuberger Berman Group first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2017 and held it in 1 quarter.
  • Neuberger Berman Group's Tetraphase Pharmaceuticals, Inc. position peaked at $141K in Q4 2017.
  • 94 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q1 2018.

Based on Neuberger Berman Group's 13F filing for Q1 2018, filed 8 May 2018.